by mpzzqmvj | Nov 11, 2022 | Press Releases
– Quarter marked by launch of Phase 2b study of Trappsol® Cyclo™ for the treatment of early Alzheimer’s Disease (AD) with patient enrollment and site activation now underway – Building momentum with ongoing advancement of global pivotal...
by mpzzqmvj | Oct 18, 2022 | Press Releases
– Data published in official journal of the Society for Inherited Metabolic Disorders, Molecular Genetics and Metabolism – Published trial data show that Trappsol® Cyclo™ overcomes the NPC1 defect by removing trapped cholesterol from cells both...
by mpzzqmvj | Oct 4, 2022 | Press Releases
Patient enrollment and site activation now underway GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing...
by mpzzqmvj | Sep 28, 2022 | Press Releases
– Company on track to commence enrollment and dosing of Phase 2 study of Trappsol® Cyclo™ for the treatment of Alzheimer’s disease before year end – Ongoing advancement of global pivotal study (TransportNPC™) evaluating...
by mpzzqmvj | Sep 7, 2022 | Press Releases
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and...
